Homepage Top Section1

This agreement grants Qilu exclusive rights to develop, manufacture, enhance, utilise and commercialise Albipagrastim alfa for Injection in Greater China including Chinese Mainland, Macau, Hong Kong and Taiwan.

Paediatric HGG, including ependymoma, are not only rare but also very difficult to treat, with current standard care failing to prevent recurrence and with five-year survival rates. Reyobiq

The application is underpinned by the multi-centre, open-label Phase III UNITI-Jr clinical trial data, which assessed the therapy’s safety, pharmacokinetics, and efficacy in paediatric subjects. At present, Stelara

This key plasma protein of Shilpa is utilised across different medical applications. It is developed using a non-human expression system that ensures scalability, high safety and virus-free production.

This agreement designates Er-Kim as the distributor for the therapy in Azerbaijan, Armenia, Belarus, Georgia, Kyrgyzstan, Kazakhstan, Uzbekistan, Tajikistan, Russia, and Turkmenistan. The prescription medicine, Nerlynx, is intended

As part of this collaboration, Boehringer will utilise ExpressionEdits’ AI-powered platform, Genetic Syntax Engine, designed to boost gene expression without altering the genetic sequence, for the development of

With this investment, Gilead’s equity ownership in Assembly Bio has increased to 29.9%. These funds are expected to extend Assembly Bio’s cash runway to mid-2026 and will support

The BLA is sought for treating NSCLC patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) who have received systemic therapies previously. Concurrently, the companies have

ALT-B4 will be used for developing the subcutaneous formulation ENHERTU. As per the agreement, Daiichi Sankyo will gain global rights to utilise Alteogen’s ALT-B4, a human recombinant hyaluronidase